

**Supplementary Table S3.** Serious TEAEs (safety population)

| <b>N=89</b>  | <b>TEAEs, n</b> |
|--|-----------------|
| <b>Infections and infestations</b>                     |                 |
| Cholecystitis infective                                | 1               |
| Influenza  | 1               |
| Pneumonia  | 1               |
| Tracheobronchitis                                      | 1               |
| <b>Respiratory, thoracic and mediastinal disorders</b> |                 |
| IPF  | 2               |
| Pneumothorax   | 3               |
| Pneumomediastinum                                      | 1               |
| <b>Neoplasm benign, malign, unspecified</b>            |                 |
| Invasive ductal breast carcinoma                       | 1               |
| Prostate cancer  | 1               |
| <b>GI disorders</b>                                    |                 |
| Pancreatitis   | 1               |
| <b>Hepatobiliary disorders</b>                         |                 |
| Cholelithiasis   | 1               |
| <b>Injury, poisoning and procedural complications</b>  |                 |
| Concussion   | 1               |
| <b>Musculoskeletal and CTD</b>                         |                 |
| Lumbar spinal stenosis                                 | 1               |
| <b>Nervous system disorders</b>                        |                 |
| TIA*   | 1               |
| <b>Vascular disorders</b>                              |                 |
| DVT*   | 1               |

\*Event considered related to treatment (nintedanib only).

CTD, connective tissue disorders; DVT, deep vein thrombosis; GI, gastrointestinal;

IPF, idiopathic pulmonary fibrosis; TEAE, treatment-emergent adverse event; TIA; transient ischaemic attack.